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Abstract: This study presents the results of the study of clinical and hemostasis predictors of mammary gland tumors in bitches, which
allow to determine the risk groups for this disease. The highest incidence rates were found in German and Eastern European Shepherds
(22.1%), Dachshunds (12.8%) and Yorkshire terriers (9.5%) when kept in private households: 97.1%, 96.3% and 97.3%, respectively.
Significantly increases the likelihood of mammary gland cancer in excess body weight – by 30%–100%, in the case of mixed feeding
– up to 39.3%, the use of hormonal contraceptives – by 50%–60%. Adverse prognosis correlates with an increase in the size, nature of
the surface and the relationship with the surrounding tissues of the lesion, localization in 4th and 5th pairs of the mammary glands.
Progression of the disease is accompanied by the development of hypercoagulable syndrome, which is characterized by an increase
in fibrinogen and soluble fibrin due to activation of external and internal coagulation pathways, as evidenced by the prolongation of
activated partial thromboplastin and prothrombin time. The results of the screening can be used for prevention and early diagnosis of
the disease, as well as the development of promising treatment protocols.
Key words: Dogs, neoplasms, mammary gland, coagulation potential, risk factors

1. Introduction
Mammary gland cancer is a complex heterogeneous group
of tumors for which it is important to find appropriate
animal models in order to discover new biomarkers and
therapeutic strategies. Occurring spontaneously, as in
humans, in 50% of cases they have signs of malignancy.
The most reliable models for this pathology are dogs that
have a significant number of human-like traits (from
pathohistological to molecular levels), which is confirmed
by the results of genome sequestration [1].
Over the past four decades, there has been an increase
in the number of similarities between mammary gland
dogs and human breast tumors: molecular, histological,
morphological, clinical, and epidemiological, leading to
comparative cancer studies [2]. The imaging methods used
are used to determine the location of the tumor, quantify
the mass of neoplasia, visualization of genes and proteins,

tumor microenvironment, proliferation and metabolism
of cancer cells, response to treatment [3].
Solid tumors are abnormal formations that consist of
several cell types and extracellular matrix. An important
aspect of the biology of tumors is their understanding not only
as clonal monocultures of cancer cells, but also as disorders of
organs acting at the level of the organism as a whole [4].
For many years, veterinary oncologists have discussed
the problem of predicting the behavior of mammary gland
tumors in dogs. Transformation of neoplasia characteristics
into prognostic information is an important tool for planning,
development and clinical implementation of innovative
treatment protocols. Collection, analysis and interpretation
of information regarding the prediction of mammary gland
neoplasms in small domestic animals are difficult due to
the use of different methodological approaches for their
evaluation [5].
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Progress in the personalization of treatment is
hampered by the lack of cancer models that take into
account individual heterogeneity within and between
types of cancer. Tumor diseases that occur in nature in
domestic animals are heterogeneous, so they allow us to
answer questions about these strategies and optimize their
interpretation for human patients [6].
Research using dogs is an ideal solution to the problem
in animal models of controversial human diseases, as
evidenced by more than 400 similar diseases of dogs and
humans. There are several hundred isolated populations of
dog breeds, each with significantly less genetic variability
than humans, which simplifies disease mapping and
pharmacogenomics [7]. In this case, long-term goals for
predicting and evaluating these types of tumors can be
achieved using a large natural resource of dogs at minimal
cost [8]. Shorter overall life expectancy and rapid disease
progression are factors that justify the superiority of the
companion animal model [9].
Despite the large number of studies on the spontaneous
manifestation of mammary gland cancer in bitches, there is
no single statistical basis that allows the analysis of clinical
cases. Low statistical reliability and underestimation of
negative results are associated, first of all, with different
methodological approaches, insufficient sampling (median
n = 33), significant fluctuations in the duration of survival
and disease progression, the high proportion of studies
with controversial randomization (44%), sample reporting
(94%), as well as the definition of the primary result (72%)
[10]. The issue of neoplasms in animals up to 12 months of
age remains insufficiently studied, which does not allow a
full assessment of sexual, breed and genetic susceptibility,
as well as the influence of oncogenic factors [11].
It has been shown that it is advisable to use indicators
of the hemostasis system as objective criteria for assessing
the malignancy risk of progression and the effectiveness of
treatment of mammary gland tumors, which in most cases
are accompanied by a hypercoagulable state [12].
Thus, mammary gland neoplasms are the most
common tumor lesions in dogs, so the study of prognostic
factors of the disease is important for standardization and
individualization of diagnostic measures and treatment
protocols.
Given the above, the aim of the study was to determine
a set of predictors of development and progression of
mammary gland tumors in bitches, which will increase the
efficiency of predicting their biological behavior.

The research was conducted following the requirements
of the European Convention for the Protection of Vertebrate
Animals (Strasbourg, 1986) and the Law of Ukraine “On
Protection of Animals from Cruelty” (2006), as confirmed
by the conclusion of the Bioethics Commission of Dnipro
State Agrarian and Economic University.
The neoplastic process in the breast was studied
by clinical and pathomorphological, anatomical and
topographic, breed, age and sex characteristics and
reproductive status, its clinical features depending on the
size of benign and malignant tumors according to the
international classification [13]. The Melbourne pain scale
(MPS), which is based on 6 criteria (total score from 0 to
27): physiological parameters, palpation response, activity,
posture, vocalization, and mental status, was used to
determine the intensity of the pain response [14]. The pain
reaction was considered as weak with a total score of 0 to
7, moderate – from 8 to 15, strong – from 16 to 27. These
patients also underwent biopsy and blood sampling for
hemostasiological analysis. A total of 791 dogs, including
603 purebreds and 188 half-blood, were examined.
We analyzed the risk of developing mammary tumors
with different modes of hormonal contraception: oral –
Pillkan 5 or Pillkan 20 (Ceva Sante Animale, Libourne,
France) at a dose of 5 mg of megesterol acetate per 2.5
kg of body weight for 8 days and injection – Depogeston
(Bioveta, Ivanovice na Hané, Czech Republic) at a dose of
50–100 mg of medroxyprogesterone aceticum per animal
once subcutaneously. Regular hormonal contraception
meant the use of pharmacological agents before each
estrus (2 times a year), irregular – their sporadic use (1
time within 1–1.5 years).
The coagulation potential was determined based
on fibrinogen content according to Belicer et al. [15],
soluble fibrin by Vareckaja et al. [16], the duration of
activated partial thromboplastin (a set of reagents from
the company Simko Ltd., Lviv, Ukraine) and prothrombin
time according to Quick [17].
To determine the pathomorphological structure
of mammary gland tumors, a biopsy was performed,
followed by verification of the histological type according
to the improved classification of Goldschmidt et al. [18].
Statistical processing of the results was performed using
Statistica 10 (StatSoft Inc., Tulsa, OK, USA). Bonferroni
corrected ANOVA was used to determine the probability
of sample difference.

2. Materials and methods
The study of risk factors for mammary gland tumors was
conducted in cooperation of Dnipro State Agrarian and
Economic University, Bila Tserkva National Agrarian
University and clinics of veterinary medicine in the city of
Dnipro during 2017–2019.

3. Results
Breed susceptibility to mammary gland cancer has been
established (Table 1): the vast majority of bitches with
mammary cancer are German and Eastern European
shepherds (22.1%), in other breeds the incidence rate is
significantly lower: in Dachshunds – 12.8%, Yorkshire

610

BІLYI et al. / Turk J Vet Anim Sci
Table 1. Frequency of registration of mammary gland tumors depending on the breed and
breeding use of bitches.
Breeding

Home
maintenance

Total

n

%

n

%

n

%

German and Eastern European shepherd

5

2.9

170

97.1

175

22.1

Dachshund

4

3.7

97

96.3

101

12.8

Yorkshire terrier

2

2.7

73

97.3

75

9.5

French bulldog

4

6.3

60

93.7

64

8.1

Rottweiler

3

7.1

39

92.9

42

5.3

Russian and English spaniel

2

5.3

36

94.7

38

4.8

Shih tzu

1

3.6

25

96.4

28

3.5

Poodle

1

3.8

25

96.2

26

3.3

Pug

1

5.3

18

94.7

19

2.4

Other breeds (registration frequency ˂ 1%)

2

5.7

33

94.3

35

4.4

Half-breed

-

-

188

100

188

23.8

791

100

Breed

Total

terriers – 9.5%, French bulldogs – 8.1%. The frequency
of registration of mammary gland tumors in bitches of
other breeds is less than in shepherds (22.1%, p ˂ 0.001).
It should be noted a significant number of breeds in which
isolated cases of mammary gland cancer were diagnosed:
within 1% of the total number within the Dnieper region,
as well as mestizos: registered in almost a quarter of cases
(23.8%). Therefore, despite significant fluctuations in the
incidence of mammary glands tumors in dogs, the most
susceptible breeds have been identified, for which medical
examination it is necessary to study the reproductive
system, in particular the mammary glands.
Analysis of the relationship between breeds and
reproductive use of bitches shows that in breeding
kennels, even among favorable breeds of dogs, the level
of registration of mammary gland tumors is from 2.7 to
7.1%, i.e. do not exceed 10%. The lowest incidence among
breeding bitches (within 3%) was found in Yorkshire
terriers (2.7%), as well as German and Eastern European
shepherds (2.9%), the maximum – French bulldogs
(6.3%) and Rottweilers (7.1%). At the same time, in the
case of keeping dogs in private households, mammary
gland neoplasia is diagnosed in 92.9%–97.3% of cases.
Such patients make up the vast majority of all cases of
mammary gland cancer in bitches. This situation may be
partly related to genetic susceptibility in some lines, but
this idea needs to be studied in detail.
Analysis of anamnestic data of cancer patients indicates
the presence of a correlation between body weight and the
likelihood of neoplastic processes in the mammary gland

of bitches (r = 0.95, p = 0.001). The minimum incidence of
mammary gland cancer has been established in individuals
whose body weight does not exceed the average parameters
of the breed. Exceeding this indicator within 20% increases
the risk of tumors by 30%, 20%–50% – 80%, more than
50%–100%. It can be assumed that excess weight causes
hormonal and metabolic imbalances, which play a key role
in the mechanisms of oncogenesis.
Given the widespread uncontrolled use of hormonal
contraceptives, their possible impact on the risk of
mammary gland tumors has been identified (Table 2).
The results show that compared to bitches who used
regular or intermittent hormonal contraception, the
absence of it reduced the risk of the disease by 50% and
60%, respectively. The ratio of the incidence of benign
and malignant neoplasms ranged from 2%, i.e. did not
depend on the mode of application of means of prevention
of sexual seeking behaviour. The obtained results do not
allow to state that violations of the hormonal status caused
by the simultaneous action of several factors (hormonal
contraception and obesity) significantly increase the risk
of mammary gland tumors.
One of the prognostic factors in the development of
mammary gland tumors is the feeding regime of animals
(Table 3). The maximum risk should be assumed in the
case of a mixed type of feeding (39.3%), which combines
the use of commercial and prepared feed, which exceeds
the corresponding indicators for use: commercial feed
(17.6%), cooked beef feed (18.6%), chicken (24.5%). The
ratio of the number of malignant tumors to benign is
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Table 2. The risk of mammary gland cancer depending on hormonal contraception.
Hormonal contraception*
Mode
Oral regular
Oral periodic
Parenteral regular
Parenteral periodic

Animals with mammary gland tumors
Total

Drug
Pillkan 5 / Pillkan 20
Depogeston

Benign

Malignant

n

%

n

%

n

%

163

20.6

75

9.5

88

11.1

202

25.5

95

12.0

107

13.5

156

19.7

70

8.8

86

10.9

194

24.5

101

12.7

93

11.8

Were not applied

76

9.6

44

5.6

32

4.0

Total

791

100

385

48.7

406

51.3

*: regular contraception - 2 times a year; irregular - once every 1–1.5 years.
Table 3. The effect of diet on the risk of mammary gland neoplasms in bitches.
Feeding ration

Animals with mammary gland tumors
Total
n

Commercial feed
Prepared feed-based

Benign
%

n

%

n

%

139

17.6

86

10.9

53

6.7

Chicken

194

24.5

86

10.9

108

13.6

Beef

147

18.6

77

9.7

70

8.9

Mixed type of feeding

311

39.3

136

17.2

175

22.1

Total

791

100

385

48.7

406

51.3

for feeding on the basis of: commercial feed – 6.7:10.9%;
prepared from chicken – 13.6:10.9%; beef – 8.9:9.7%, and
mixed type – 22.1:17.2%.
One of the main predictors of mammary gland
cancer in dogs is their pathomorphological structure.
Malignant neoplasms of the mammary gland in bitches
are characterized by a wide variety of histological types,
which complicates the prediction of the disease. Malignant
epithelial tumors were most often diagnosed (33.1% of
the total number of neoplasms), while the frequency of
verification of special types of epithelial neoplasms and
osteosarcoma was lower – 9.7% and 8.7%. In most cases,
among the epithelial types of malignant neoplasms of the
mammary gland in dogs, carcinomas of complex, mixed
type and in situ are registered: in 6.8, 5.7 and 5.3% of the
total number of cancer animals. Inflammatory carcinoma
(5.3%) and osteosarcoma (7.3%) are often diagnosed
among specific epithelial tumors.
Among benign types of mammary gland tumors in dogs,
the most common are complex adenoma, fibroadenoma
and benign mixed neoplasia with rates of 25.5%, 23.8%,
and 22.3%, respectively, accounting for more than 70% of
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Malignant

cases. The incidence of other benign neoplasms (simple,
intraductal papillary and ductal adenomas) ranged from
4% to 5%.
Analysis of clinical signs of mammary gland tumors
in dogs indicates a change in the nature of their surface,
depending on the stage and size of the lesion, which
indirectly indicates the transition from benign to malignant
(Table 4). In the benign course within stages 1–3 of the
disease there is a change in the ratio of neoplasms with a
smooth and bumpy surface: at a small size (up to 3 cm)
it was 88.2:11.8%, 3–5 cm – 70.5:29.5%, and more than 5
cm – 58.9:41.1%. At the same time, areas of necrosis were
registered, starting from the average size of tumors (3–5
cm) with an increase in their frequency with an increase
in tumors to 12.3%. A similar situation with invasion into
the surrounding tissues. In particular, the number of cases
of involvement in the neoplasia of the skin, compared
with small tumors (< 3 cm) – 5.9%, increased to 16.4%.
The spread of the tumor to adjacent muscles was found
only at their average and giant size against the background
of an increase in the frequency of invasion with disease
progression to 10.1%. At the same time, the pain response
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intensifies, but a significant difference is found between
the group T3/T4 and T1 (p ˂ 0.001) and T2 (p ˂ 0.05). The
size of the tumor, the relationship with the surrounding
tissues and the degree of expression of the inflammatory
reaction allow to determine the extent of surgery.
In animals with malignant tumors of the mammary
gland stages 1–3, the ratio of the number of neoplasms
with a smooth surface to the hump with the progression
of the disease varies from 84.6:15.4% to 35.4:64.6%, and in
4th stage is 16.7:83.3% (Table 5).
In this case, in contrast to dogs with benign neoplasms,
already at the size of 3–5 cm, they are registered with
approximately the same frequency, and later tumors with
a bumpy surface begin to prevail. Necrotic defects were
registered even at small neoplasia foci, although only in
3.8% of cases. The progression of the disease is characterized
by an increase in their frequency in stages 1–3 to 45.6%,
stage 4 – 66.7%. A sharp increase in the percentage of such

patients with an increase in size to 3–5 cm is noteworthy.
A similar situation is observed about the invasion of the
surrounding tissues: the skin – 11.5%–77.8%, muscles
3.8%–83.3%. At the same time, with an increase in the size
of mammary gland tumors in dogs, there is an increase in
the intensity of pain in stages 1–3 from 4 ± 0.6 to 20 ± 3.1
points, but a statistically significant difference was found
between groups T3/T4 (stages 1–3) and T1–T4 compared
with T1 (p ˂ 0.001) and T2 (p ˂ 0.05). Clinical changes in
mammary gland tumors have prognostic value only when
used in a comprehensive assessment.
Monitoring the spread of mammary gland tumors in
terms of age, depending on its stage and size of neoplasia
foci revealed some patterns (Table 6). The maximum
frequency of registration of small benign neoplasms, up to
3 cm in stages 1–3, is set at the age of 1–3 and 6–8 years,
the minimum – up to six months and older 12 years, and
malignant – 1–5 and younger 6 months, respectively.

Table 4. Clinical characteristics of different stages of benign mammary gland tumor in dogs (%).
Stages 1–3

Clinical criteria
Т1 (< 3 cm)
The nature of the surface

Т2 (3–5 cm)

Т3/Т4 (˃ 5 сm)

Smooth

88.2

70.5

58.9

Hilly

11.8

29.5

41.1

-

6.8

12.3

5.9

9.1

16.4

-

4.5

10.1

2 ± 0.6

4 ± 1.5

15 ± 3.7***°

Areas of necrosis
Skin

Invasion into the surrounding tissues

Muscles

Intensity of pain reaction♦

***: p ˂ 0.001 compared with tumors Т1, °: p ˂ 0.05 compared with tumors Т2;
♦
: Melbourne pain scale (MPS) in points: weak 0–7, moderate 8–15, strong 16–27.
Table 5. Criteria for clinical evaluation of malignant neoplasms of the mammary
gland in dogs (%).
Stages 1–3

Clinical criteria
Т1
(< 3 cm)
The nature of the
surface

Т2
(3–5 cm)

Т3/Т4
(˃ 5 сm)

Т1–Т4
(various)

Smooth

84.6

53.8

35.4

16.7

Hilly

15.4

46.2

64.6

83.3

areas of necrosis
Invasion into the
surrounding tissues

Stage 4

3.8

17.9

45.6

66.7

Skin

11.5

25.6

36.7

77.8

Muscles

3.8

15.4

4 ± 0.6

9 ± 3.5

55.7
20 ±
3.1***°

83.3
22 ±
4.4***°

Intensity of pain reaction

♦

***: p ˂ 0.001 compared with tumors Т1, °: p ˂ 0.05 compared with tumors Т2;
♦
: Melbourne pain scale (MPS) in points: weak 0–7, moderate 8–15, strong 16–27.
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Table 6. Stage of tumors depending on the age of patients (%).
Stages 1–3

Stage 4

Т1
(< 3 cm)

Т2
(3–5 cm)

Т3 / Т4
(˃ 5 сm)

Т1–Т4
(various)

b*

m**

b*

m**

b*

m**

m**

˂ 0.5

5.9

3.9

2.2

5.1

4.1

3.8

-

0.5–1

5.9

7.7

6.8

7.7

6.9

8.9

-

1–3

23.5

34.5

15.9

23.1

15.1

10.1

5.6

4–5

17.7

23.1

34.1

15.4

26.0

12.7

11.1

6–8

23.5

11.5

18.2

25.6

16.4

27.9

22.2

9–11

17.7

11.5

11.4

12.8

16.4

17.6

44.4

≥ 12

5.9

7.7

11.4

10.3

15.1

19.0

16.7

Age, years

b*: benign, m**: malignant tumor of the mammary gland.

At the same time, in 1–5-year-old dogs, the percentage
of malignant tumors (3.9%–23.1%) exceeded the
corresponding indicators for benign ones (5.9%–17.7%),
while in 6–11-year-old bitches it was lower. In dogs,
malignant neoplasms ranging in size from 3 to 5 cm in
young animals (up to 0.5 years) were found in 5.1%, in 1–3
years – 23.1%, 6–8 years – in 25.6% of patients.
That is, neoplasms of this size were characteristic of
middle-aged dogs. In the case of an increase in the size
of tumors of stages 1–3, the shift of emphasis on their
localization is established. In particular, the frequency
of benign neoplasms larger than 5 cm gradually
increases with a maximum in 4–5-year-old animals with
a subsequent decrease in their registration, while the
highest probability of malignant tumors occurs at the age
of 6–8 years. Malignant neoplasms of stage 4 are diagnosed
starting from one year, the frequency of their registration
increases sharply in 9–11-year-old dogs (44.4%): twice,
compared with 6–8-year-old animals (22.2%), with a
subsequent decrease of 2.7 times in animals older than
12 years (16.7%). Thus, the incidence of mammary gland
tumors is minimal in bitches before one and after twelve
years.
The established features of tumor localization in dogs
indicate that benign neoplasms of small size (< 3 cm) are
located in most cases in 2–4th pairs, while malignancies
are more often diagnosed in 3th and 5th pairs of mammary
glands (Table 7). In benign neoplasms 3–5 cm in size, a
similar situation is observed, while in malignant tumors
in the vast majority of cases affect 4th and 5th pairs of
mammary glands. In particular, their percentage is 9.1:10.3
for 1th pair, 22.7:12.8% – 2th pair; 22.7:15.4% – 3th pair.
For tumors larger than 5 cm, the minimum frequency of
their registration, regardless of the nosological profile, is
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characteristic of the first pair, the maximum – the 3th–5th
pairs of the mammary gland. At the same time, if benign
tumors are characterized by an increase in the number of
cases with a maximum of 5th pairs, then for malignant –
in 4th pairs against the background of a decrease in the
frequency of localization in 5th pairs. In stage 4, malignant
neoplasms in the vast majority of cases are located in 4th
and 5th pairs of mammary glands: the total number of
such patients is 72.1% of all dogs in this group.
Analysis of functional disorders of the hemostasis
system in cancer patients is characterized by activation of
coagulation cascades, the intensity of which correlates with
the stage and size of the tumor, as well as the histological
type of tumor (Table 8). In particular, compared with
clinically healthy animals, the content of fibrinogen in
benign tumors 1–3th stages (p ˂ 0.001): ˂ 3 cm increased
up to 4.1 ± 0.09 g/L, from 3 to 5 cm – 9.4 ± 0.8 g/L,
more than 5 cm – 11.5 ± 0.5 g/L, and malignant – 6.0 ±
0.03; 12.3 ± 0.7; 17.2 ± 1.1 g/L, respectively. At the same
time, regardless of the stage and size of neoplasms, its
concentration in malignant neoplasms of the mammary
gland significantly exceeded the corresponding indicators
of patients with benign tumors (p ˂ 0.01).
Similar dynamics are also characteristic of the content
of soluble fibrin. The progression of the disease was
accompanied by its accumulation with the maximum
level in bitches in 4th stage of cancer: 22.6 ± 2.3 mg/dL.
In contrast to the fibrinogen content, the concentration of
soluble fibrin in the malignant course differed significantly
(p ˂ 0.001) from the benign one only starting from stage
T2 (3–5 cm).
The development of hypercoagulable syndrome is
realized both externally and internally, as evidenced
by changes in the duration of the activated partial
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Table 7. Localization of mammary gland tumors in dogs (%).
Stages 1–3
Mammary
gland pairs

Stage 4

Т1
(< 3 cm)

Т2
(3–5 cm)

Т3 / Т4
(˃ 5 сm)

Т1–Т4
(various)

b*

m**

b*

m**

b*

m**

m**

1

11.8

11.5

9.1

10.3

8.2

6.3

5.6

2

23.5

19.2

22.7

12.8

12.3

17.7

5.6

3

23.5

23.2

22.7

15.4

23.3

26.6

16.7

4

23.5

19.2

27.3

28.2

27.4

29.1

33.3

5

17.7

26.9

18.2

33.3

28.8

20.3

38.8

b*: benign, m**: malignant tumor of the mammary gland.
Table 8. Metabolism of fibrinogen in bitches depending on the size of neoplasms.

Indicator
Сlinically healthy

Fibrinogen, g/L
b*

Soluble fibrin, mg/dL
m**

b*

2.2 ± 0.1

m**

0.1 ± 0.01

Stages 1–3
Т1 (< 3 cm)

4.1 ± 0.09°°°

6.0 ± 0.03°°°♦♦

0.5 ± 0.01°°°

0.7 ± 0.08°°°

Т2 (3–5 cm)

9.4 ± 0.8°°°

12.3 ± 0.7°°°♦♦

5.9 ± 0.4°°°

9.9 ± 0.6°°°♦♦♦

Т3 / Т4 (˃ 5 сm)

11.5 ± 0.5°°°

17.2 ± 1.1°°°

7.1 ± 1.2°°°

13.1 ± 1.2°°°♦♦♦

-

25.7 ± 1.8°°°

-

22.6 ± 2.3°°°

♦♦

Stage 4
Т1–Т4 (various)

b*: benign, m**: malignant tumor of the mammary gland; °°°: p ˂ 0.001 relatively clinically healthy animals;
♦♦
: p ˂ 0.01, ♦♦♦: p ˂ 0.001relatively benign tumors.

thromboplastin and prothrombin pathways (Table 9). In
both cases, their elongation is registered, compared with
clinically healthy dogs. The increase in the size of malignant
neoplasms was accompanied by a progressive increase in
the duration of activated partial thromboplastin time in
patients with stages 1–3 up to 55.7 ± 1.0 –68.9 ± 3.1 s (p ˂
0.05–0.01) times, stage 4 – 81.5 ± 3.4 s (p ˂ 0.001). In the
case of benign tumors, this indicator does not depend on
the clinical stage of the disease and the histological type of
tumors. In contrast to the activated partial thromboplastin
time, the prothrombin time was prolonged in all cases as
the process progressed (p ˂ 0.001): for foci up to 3 cm in
benign course – up to 11.7 ± 1.2 s, malignant – 17.7 ± 0.9 s;
3–5 cm – 14.3 ± 1.2 and 21.0 ± 1.3 s; more than 5 cm – 17.0
± 0.7 and 24.6 ± 1.3 s, respectively. In dogs with malignant
neoplasms, the prothrombin time was significantly (p ˂
0.01) higher than in patients with benign tumors.
Certain disorders of hemostasiological status suggest
a high risk of thrombosis in dogs with cancer, thereby

contributing to metastasis, which is the leading cause of
death in such patients.
4. Discussion
Our results are consistent with the reports of other
researchers on the negative trend to increase the incidence
of malignant tumors (up to 70%) of the mammary gland
relative to benign neoplasms (30%), the peak of their
registration (60%) in 8–13-year-old bitches [19]. Some
reports indicate a high prevalence of mammary tumors
among certain breeds (Samoyeds, Dobermans, Schnauzers,
Yorkshire terriers) due to genetic susceptibility [20],
although our studies do not confirm this pattern.
The increase in the incidence of mammary gland
cancer is probably due to the high intensity of life in
the metropolis, the inability of animals to adapt to such
conditions and, as a result of stress, as evidenced by the
results of Cannas et al. [21] regarding the presence of a
correlation (p < 0.05) between stress and the frequency
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Table 9. The state of the external and internal blood clotting pathways for tumors.

Indicator
Сlinically healthy

Activated partial thromboplastin
time, sec.

Prothrombin time, sec.

b*

b*

m**

46.1 ± 1.3

m**

8.7 ± 0.9

Stages 1–3
Т1 (< 3 cm)

49.5 ± 0.6

55.7 ± 1.0°

11.7 ± 1.2°°°

17.7 ± 0.9°°°♦♦

Т2 (3–5 cm)

53.5 ± 1.1°

62.8 ± 3.6°°♦

14.3 ± 1.2°°°

21.0 ± 1.3°°°♦♦

Т3 / Т4 (˃ 5 сm)

59.7 ± 1.0°°

68.9 ± 3.1°°

17.0 ± 0.7°°°

24.6 ± 1.3°°°♦♦

-

81.5 ± 3.4°°°

-

30.2 ± 1.5°°°

♦

Stage 4
Т1–Т4 (various)

b*: benign, m**: malignant tumor of the mammary gland; °: p ˂ 0.05, °°: p ˂ 0.01, °°°: p ˂ 0.001
relatively clinically healthy animals; ♦♦: p ˂ 0.05, ♦♦♦: p ˂ 0.01 relatively benign tumors.

of this pathology in dogs. At the same time, clinical signs
according to the international classification of stages of
malignant neoplasms (TNM: size of the primary tumor,
presence or absence of metastases in regional lymph nodes
and distant tissues) are of important prognostic value, but
in combination with histological verification of tumors.
The incidence, macropathological changes and
pathological type of neoplasia do not correlate with longterm survival, while the number of metastases, maximum
tumor diameter, TNM stage and hormone receptor levels
significantly affect the duration of the recurrence-free
period [22].
The results of our study are consistent with the opinion
of Sorenmo et al. [23] regarding the fact that malignant
tumors are recorded in older animals (9.5 versus 8.5 years,
p = 0.009), their sizes exceed benign ones (4.7 versus
2.1 cm, p = 0.0002) by against the background of a high
likelihood of developing new primary neoplasias (p =
0.0015). Giant tumors (T3) in most cases are characterized
by malignancy, lower progesterone receptor expression
and high markers of cell proliferation, as well as a shorter
survival period, which confirms the importance of tumor
size as a prognostic indicator of mammary gland tumors
in bitches [24], in particular for adenocarcinoma [25].
The most commonly diagnosed mammary gland cancer is
stage 1 (31.75%), less often stages 2–5 [26].
Regardless of the observation period and location,
in a study of a significant number of patients, the ratio
of spontaneous malignant and benign mammary gland
tumors in dogs is about 1:1, which coincides with the
incidence in humans [27]. In contrast to several indicators
that vary significantly depending on the region (breed,
frequency of registration of neoplasms of different sizes),
in the vast majority of cases, tumor foci are located in the
fourth and fifth pairs of mammary glands, and risk factors
are age (p < 0.001), overweight (p = 0.048) and failure to
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perform ovariohysterectomy (p < 0.001) [28]. In addition,
we additionally established a correlation between tumor
localization and their staging, in particular, verification
in 72.1% of stage 4 neoplasms in caudal abdominal and
inguinal pairs of the mammary gland.
The highest probability of developing tumors in the last
pair of the mammary gland (fourth – in 27%, fifth – 60%
of dogs), due to the duration of growth before diagnosis,
age of patients and high prevalence of stray animals [29],
consistent with Gomes et al. [30] data: the frequency of
lesions of the inguinal mammary glands in dogs reaches
66.6%–70%.
Obesity is a growing concern for pet owners, and the
increase in morbidity associated with it reflects a general
trend that is also observed in humans. The results obtained
on obesity as a risk factor for mammary gland tumors are
consistent with data from other researchers, who indicate
a high risk of neoplasia transformation of functional tissue
in the presence of excess weight in both humans and
dogs [31]. Against the background of a significant overall
prevalence of obese dogs (21.6%), a significant difference
in the incidence of cancer depending on the bodyweight
of animals. The prevalence of overweight dogs varied
depending on the specific histological types of cancer
[32]. In mammary gland cancer, obese and overweight
bitches showed a shorter survival rate than animals that
were normal weight. A positive correlation was established
between body composition (fatness) and histological class
(p ˂ 0.01). According to the presented results, bitches had
a higher body weight in the home diet, compared with
feeding commercial feed, against the background of no
dependence on the incidence of mammary gland cancer
[33].
Overweight animals can influence the development
and behavior of mammary gland tumors due to the
interaction of neoplasia-adipocytes and increased growth
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of tumors associated with HR-receptors. Dogs with excess
body weight are characterized by a younger age of patients
(8.7 ± 1.9 years), a higher proportion of low-differentiated
(grade III) tumors, a direct correlation between high
levels of aromatase expression and HR (p = 0.025) [34].
In addition, in dogs, similarly to humans, overweight
is marked by a significant increase in prostaglandin E2
(PGE2), which correlates with the expression of aromatase,
transcription factor NF-κB and leptin, but in the absence
of a relationship with pathomorphological changes in
mammary tissues [35].
The presented explanations for obesity-related
cancer emphasize the direct mutagenic effects of feeding
components or hormonal imbalances. One of the main
tasks should be to differentiate between factors that
independently contribute to obesity or cancer and
those that cause carcinogenesis indirectly. Against the
background of obesity, according to the first hypothesis,
chronic inflammation causes the initiation of the
kynurenine pathway, which leads to activation of the aryl
hydrocarbon receptor (AhR) and modulation of synaptic
transmission in the brain. According to the second
hypothesis, serine proteases are able to deplete the cells of
neoplasia suppressors [36].
The established heterogeneity of the structure of
mammary gland tumors confirms the opinion of other
researchers on the significant variability of their biological
behavior and the need to find new prognostic and
therapeutic factors, taking into account the individual
characteristics of each patient [37]. Morphological and
biological heterogeneity based on molecular analysis
and classification Goldschmidt et al. [18], as well as the
frequency of registration of malignant types at 52% is
confirmed by Im et al. [38].
The expediency of pathomorphological verification is
confirmed by the importance of tumor size as a predictor
of recurrence and metastasis. A 10-fold risk of death
from oncogenesis has been shown to be associated with
tubulopapillary, intraductal papillary carcinoma, and
malignant myoepithelial tumors. The most unfavorable
prognosis is characteristic of anaplastic carcinoma and
carcinosarcoma: the frequency of metastases is 89%
and 100%, respectively, as well as adenosquamous
carcinoma: the probability of recurrence reaches 50%
[39]. A significant number of osteosarcomas verified in
our study are due to myoepithelial differentiation, with a
key role in the chondrogenesis of regulatory proteins [40].
Kim et al. [41] found a significant correlation (p ˂ 0.05)
between the size and breed of dogs, histological type and
molecular phenotype in Shih Tzu dogs. In our opinion, this
dependence is debatable, due to different methodological
approaches to the diagnosis of tumors.

The established prognostic significance of the
pathomorphological structure of neoplasms is
supplemented by publications of other researchers. In
particular, Scarpa et al. [42] showed the importance of
determining the presence of tumor cells in the area of
the edges of the operating field: the recurrence rate of
infiltrated or slightly contaminated was significantly
higher compared to clean edges. In malignant types, some
researchers indicate the prognostic value of tumor necrosis,
the volume of which depends on the intensity of local and
systemic inflammatory reactions and affects survival, in
the absence of correlation with the pathological stage [43].
Clinical stage, histological class, the involvement of
sentinel lymph nodes, and sterilization status can be used
as single criteria as independent prognostic variables to
determine survival as well as the likelihood of recurrence
and metastasis in mammary gland tumors in dogs [44].
In particular, low probability of survival can be predicted
in older animals, with invasive growth, significant tumor
size, the presence of ulcerative skin lesions and regional
lymph node involvement. [45].
Our results are consistent with the general patterns
of disorders of the hemostasis system and endothelial
function in mammary gland tumors and indicate their
strengthening in the case of increasing the size of neoplastic
foci, which may indicate an increase in the aggressiveness
of tumors. In dogs in the presence of prothrombotic
diseases, a significant decrease in fibrinolysis activity is
registered, and their development against the background
of a systemic inflammatory reaction, in particular in
cancer patients, causes a maximum decrease in the level
of fibrinolytic potential [46]. In particular, the expression
of tissue factor, which plays an important role in the
pathogenesis of this pathology, affects the intensity of
thrombin formation – the main link in the mechanism
of blood clotting [47]. Increased tissue factor activity has
been shown to correlate with D-dimer levels in dogs with
pathology accompanied by disseminated intravascular
coagulation syndrome [48].
Even though the data obtained are consistent with the
results of other researchers, according to which mammary
gland cancer in bitches is accompanied by a hypercoagulable
state, although the syndrome of disseminated intravascular
coagulation has been diagnosed relatively rarely. The
most common hemostatic disorders found in dogs with
carcinoma are hypercoagulation, thrombocytosis in 46%
of cases, hyperfibrinogenemia in 32% of patients with
decreased levels of activator inhibitor plasminogen [49].
The increase in procoagulant status and facilitation of
metastasis is caused by increased expression of tissue
factor, which depends on the content of antithrombin and
plasminogen in the absence of its correlation with stage
and degree of malignancy [50].
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The systemic inflammatory reaction that accompanies
the neoplasia process can cause a hypocoagulable state
characterized by (p < 0.001) a decrease in antithrombin
(AT), FVIII and the ratio activated protein C (APC) [51].
In our opinion, further research in this direction is
expedient, which will probably allow to study in more
detail the connection of hemostasiological balance with
other factors that cause malignancy of neoplasms [52].
In animals with mammary gland tumors there
is hyperactivation of the hemostasis system due to
thrombinemia, as evidenced by the appearance in the
blood plasma of soluble fibrin, but the wide range of
its parameters cannot be clear clinical and hemostasis
criteria of the neoplasia, but only a pathognomonic sign
of coagulation. hemostasis, regardless of their types. The
high concentration of soluble fibrin in the blood is a
consequence of the functioning of the tumor, which not
only directly produces thrombin, but also affects the tissue
factor, activating its conversion from prothrombin. It is
also a response to the increased levels of interleukin-6,
which is secreted by macrophages, which is confirmed by
some authors.
However, the dynamic increase in soluble fibrin
concentration, especially in the case of malignant
tumors, undoubtedly indicates the permanence of the
hypercoagulant process of tumor growth, which was
characterized by an increase in plasma concentration
of soluble fibrin in the absence of statistically significant
difference
To assess the internal pathway and the general
cascade of the blood coagulation system, it is advisable
to determine the activated partial thromboplastin time,
which, among global indicators of coagulation, is the most
sensitive and allows to assess not only the degree of its
activation but also the deficiency of plasma coagulation
factors disseminated intravascular coagulation syndrome
[53].
The established prolongation of the activated partial
thromboplastin time may be due to a deficiency or
defect of plasma coagulation factors, which is evidence
of coagulopathy of consumption as one of the stages
of disseminated intravascular coagulation syndrome.

This, on the one hand, weakens the biological barriers
and creates the conditions for tumor aggression; on
the other hand, there is a risk of both thrombosis and
bleeding during surgical removal of tumors. Therefore,
the rate of activated partial thromboplastin time may be
a significant paraneoplastic hemostasiological criterion in
the diagnosis and prognosis and treatment of animals with
breast neoplasms, especially of malignant origin.
Indicators of the prothrombin test in any case confirm
the formation of hypercoagulable syndrome in mammary
gland tumors of different genesis in dogs. Its reduction
reflects the first stages of activation of hemostasis, which
gradually leads to a deficiency of plasma coagulation
factors or to their inhibition by the secretory products of
tumor cells. Thus, the change in prothrombin time may
also be a paraneoplastic criterion for mammary gland
tumors in dogs.
Although the aggression of tumor cells to increase their
range is due to their own proteolytic systems and including
tissue plasminogen activators [54], but for the most part
the latter are suppressed [55], as proved above, especially
in the case of malignant neoplasms.
Thus, despite the urgency of the problem of tumors in
dogs, there are no short-term prospects for its solution.
It is important to screen the disease in different regions,
the analysis of the results of which will form a unified
methodological approach, to determine the role of
causative factors in the initiation of the mechanism of
oncogenesis. Analysis of monitoring studies of clinical
and hemostasiological features of the course of mammary
gland tumors in bitches will minimize the development
of recurrences and metastases, primarily due to early
diagnosis of the disease. The presence of disorders of
hemostasiological status justifies the feasibility of use
in the treatment of low molecular weight heparins and
nonsteroidal antiinflammatory drugs.
Comprehensive
assessment
of
clinical,
pathomorphological and hemostasiological parameters at
the initial examination of bitches with mammary glands
tumors allows with a high level of reliability to predict
the course of the disease and apply optimal treatment
protocols.
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